Indefinite Delivery Contract 75N91024D00002
Award Date
1/25/24
Last Date to Order
1/24/29
Federal Agency
National Cancer Institute
Awardee
University Of Illinois
Ultimate Awardee
University Of Illinois
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Employment Eligibility Verification
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The University of Illinois, doing business as The Board of Trustees of the University of Illinois, has been awarded an Indefinite Delivery Contract (IDC) from the National Cancer Institute (NCI), a part of the U.S. Department of Health and Human Services, to support the PREVENT Cancer Preclinical Drug Development Program. This multiple-award IDC, valued at up to $149,995,000, aims to provide a structured approach to the development of cancer drugs and vaccines from discovery through clinical...
The University of Illinois, through The Board of Trustees of the University of Illinois, holds an Indefinite Delivery Indefinite Quantity (IDIQ) contract from the National Cancer Institute (NCI) to support the PREVENT Cancer Preclinical Drug Development Program. This $149,995,000 multiple-award contract aims to provide a structured approach to the development of cancer drugs and vaccines from discovery through clinical trials. The contract includes three separate pools: evaluating the efficacy...
The University of Illinois, doing business as The Board of Trustees of the University of Illinois, has been awarded an Indefinite Delivery Contract (IDC) from the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services. The $19,000,000 multiple-award IDC, designated as the "PREVENT Toxicology and Pharmacology Testing (PREVENT TOX)" program, aims to provide a structured approach to the development of cancer drugs and vaccines from...
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $74,995,000 multiple-award contract, titled the "PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers," supports preclinical efficacy and biomarker evaluation, manufacturing, and...
The National Cancer Institute (NCI) awarded a multiple-award Indefinite Delivery Contract (IDC) with a $149,995,000 ceiling value to The Institute For Cancer Research, a non-profit organization and subsidiary of Temple University, to provide preclinical efficacy and biomarker analysis services in support of the PREVENT Cancer Preclinical Drug Development Program. This 5-year IDC contract includes three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product...
The National Cancer Institute (NCI) awarded a $74,995,000 multiple-award indefinite delivery/indefinite quantity (IDIQ) contract called the PREVENT Preclinical Drug Development Program to support preclinical pharmacology, toxicology, and product development services for cancer therapy candidates. The prime contractor, IIT Research Institute (IITRI), is a non-profit division of the Illinois Institute of Technology that specializes in these preclinical services for federal agencies. Under this...
The contract IDV award is for the PREVENT Cancer Preclinical Drug Development Program, a multiple-award IDIQ contract administered by the National Cancer Institute (NCI). The program encompasses three main technical areas: (1) evaluation of the efficacy and pharmacodynamic/efficacy biomarkers for potential cancer preventive agents, (2) preclinical product development, analytical testing, process development, and cGMP manufacturing support for cancer preventive vaccines, and (3) pharmacological...
The University of Texas MD Anderson Cancer Center was awarded an indefinite delivery, indefinite quantity (IDIQ) contract from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to support the PREVENT Preclinical Drug Development Program. This multiple award IDIQ has a $74,995,000 ceiling and a 5-year base period with a 5-year option. It covers three pools of services: preclinical efficacy and biomarker evaluation, preclinical GMP product development and...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a multiple-award indefinite delivery/indefinite quantity (IDIQ) contract to Weill Medical College of Cornell University to provide preclinical research services for the PREVENT Cancer Preclinical Drug Development Program. Under this $149,995,000 IDIQ, the contractor performs efficacy testing, biomarker evaluation, and analytical assay development to advance cancer...
The Indefinite Delivery Contract (IDC) with ID 75N91024D00006 was awarded by the National Cancer Institute (NCI), a civilian agency, to the Weill Medical College of Cornell University. This multiple-award IDC, with a ceiling value of $149,995,000, supports the PREVENT Cancer Preclinical Drug Development Program through the provision of preclinical research services. The IDC's scope includes evaluating the efficacy of potential cancer preventive agents, identifying relevant biomarkers, developing...